Actively Recruiting
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
Led by University Health Network, Toronto · Updated on 2026-03-05
52
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.
CONDITIONS
Official Title
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- ECOG performance status of 0 to 2
- Willing and able to provide informed consent
- Metastatic melanoma confirmed by imaging and clinical diagnosis
- Receiving first-line immunotherapy or BRAF inhibitors
- Up to 10 extracranial progressive metastatic sites, no limit on total metastatic lesions
- Prior radiation near or overlapping oligoprogressive sites allowed
- All oligoprogressive sites suitable for SBRT or hypofractionated radiotherapy
You will not qualify if you...
- More than 10 extracranial progressive disease sites
- Pregnancy
- Leptomeningeal disease
- Serious medical conditions preventing radiotherapy such as ataxia-telangiectasia or scleroderma
- Prior radiotherapy near oligoprogressive lesions exceeding organ tolerance preventing SBRT
- Psychological, sociological, or geographical issues interfering with study compliance
- Any other condition deemed inappropriate by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada
Actively Recruiting
Research Team
J
Jillian C Tsai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here